Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varlilumab and Nivolumab in Relapsed or Refractory Aggressive B-cell Lymphomas
NCT03038672Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2018
- Primary completion
- May 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of varlilumab in B-cell non-Hodgkin lymphoma, sponsored by National Cancer Institute. Started Dec 2018; status: active, not recruiting.
02
Drugs
varlilumab
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT03038672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03038672.